Laboratory Corp. of America Holdings (NYSE:LH) has been given an average rating of “Hold” by the twenty-one research firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $174.15.

Several equities research analysts have commented on the company. Wolfe Research assumed coverage on Laboratory Corp. of America in a report on Tuesday, April 2nd. They issued an “underperform” rating on the stock. Barclays boosted their target price on Laboratory Corp. of America from $165.00 to $173.00 and gave the stock an “overweight” rating in a report on Monday, March 18th. Jefferies Financial Group upgraded Laboratory Corp. of America from a “hold” rating to a “buy” rating and boosted their price target for the stock from $154.00 to $190.00 in a research note on Tuesday, April 2nd. ValuEngine upgraded Laboratory Corp. of America from a “sell” rating to a “hold” rating in a research note on Monday, March 11th. Finally, Morgan Stanley set a $175.00 price target on Laboratory Corp. of America and gave the stock a “buy” rating in a research note on Friday, February 22nd.

In related news, Director R Sanders Williams sold 1,038 shares of the company’s stock in a transaction on Wednesday, February 13th. The stock was sold at an average price of $147.00, for a total transaction of $152,586.00. Following the completion of the sale, the director now owns 8,924 shares in the company, valued at $1,311,828. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.74% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of LH. Norges Bank purchased a new stake in Laboratory Corp. of America during the fourth quarter valued at $120,695,000. BlackRock Inc. increased its position in Laboratory Corp. of America by 6.9% during the fourth quarter. BlackRock Inc. now owns 9,772,113 shares of the medical research company’s stock valued at $1,234,806,000 after acquiring an additional 633,105 shares during the last quarter. Rehmann Capital Advisory Group increased its position in Laboratory Corp. of America by 16,859.4% during the third quarter. Rehmann Capital Advisory Group now owns 544,566 shares of the medical research company’s stock valued at $1,062,784,000 after acquiring an additional 541,355 shares during the last quarter. Brandes Investment Partners LP increased its position in Laboratory Corp. of America by 559.8% during the fourth quarter. Brandes Investment Partners LP now owns 345,870 shares of the medical research company’s stock valued at $43,703,000 after acquiring an additional 293,453 shares during the last quarter. Finally, Morgan Stanley increased its position in Laboratory Corp. of America by 30.9% during the third quarter. Morgan Stanley now owns 1,006,695 shares of the medical research company’s stock valued at $174,843,000 after acquiring an additional 237,918 shares during the last quarter. Institutional investors own 91.50% of the company’s stock.

Laboratory Corp. of America stock opened at $159.07 on Tuesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.51. Laboratory Corp. of America has a 12 month low of $119.38 and a 12 month high of $190.35. The firm has a market capitalization of $15.58 billion, a price-to-earnings ratio of 14.43, a P/E/G ratio of 1.79 and a beta of 1.15.

Laboratory Corp. of America (NYSE:LH) last released its earnings results on Thursday, February 7th. The medical research company reported $2.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.48 by $0.04. Laboratory Corp. of America had a return on equity of 17.05% and a net margin of 8.43%. The business had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.78 billion. During the same period in the previous year, the company posted $2.45 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. On average, research analysts predict that Laboratory Corp. of America will post 11.22 EPS for the current year.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Read More: What is the NASDAQ?

Analyst Recommendations for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.